benzphetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 329 | 156-08-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 10.44 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 0 | Hosey CM, Chan R, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 26, 1960 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA PE | N0000175372 | Appetite Suppression |
| FDA EPC | N0000175423 | Sympathomimetic Amine Anorectic |
| CHEBI has role | CHEBI:35524 | sympathomimetic |
| CHEBI has role | CHEBI:35640 | adrenergic uptake inhibitors |
| CHEBI has role | CHEBI:51039 | dopamine reuptake inhibitor |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018759 | Adrenergic Uptake Inhibitors |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D000697 | Central Nervous System Stimulants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018765 | Dopamine Uptake Inhibitors |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| FDA PE | N0000175651 | Increased Sympathetic Activity |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Obesity | indication | 414916001 | DOID:9970 |
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Bipolar disorder | contraindication | 13746004 | DOID:3312 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Feeling agitated | contraindication | 24199005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Angina pectoris | contraindication | 194828000 | |
| Mania | contraindication | 231494001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.71 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Transporter | RELEASING AGENT | CHEMBL | CHEMBL | |||||
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | CHEMBL | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | WOMBAT-PK | |||||||
| Alpha-1A adrenergic receptor | GPCR | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019628 | VUID |
| N0000147721 | NUI |
| 5411-22-3 | SECONDARY_CAS_RN |
| 1422 | RXNORM |
| C0005096 | UMLSCUI |
| CHEBI:3044 | CHEBI |
| CHEMBL3545985 | ChEMBL_ID |
| DB00865 | DRUGBANK_ID |
| CHEMBL3544906 | ChEMBL_ID |
| D001589 | MESH_DESCRIPTOR_UI |
| 5311017 | PUBCHEM_CID |
| 978 | INN_ID |
| 0M3S43XK27 | UNII |
| 109114 | MMSL |
| 4262 | MMSL |
| d00807 | MMSL |
| 386111003 | SNOMEDCT_US |
| 6088007 | SNOMEDCT_US |
| 67428007 | SNOMEDCT_US |
| 4018067 | VANDF |
| 4019628 | VANDF |
| 001800 | NDDF |
| 004725 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-040 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-040 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12634-118 | TABLET | 50 mg | ORAL | ANDA | 21 sections |
| benzphetamine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17224-672 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-458 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-081 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 21 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-541 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-541 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-541 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-541 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1024 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1024 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5837 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 21 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5837 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 21 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53217-175 | TABLET | 50 mg | ORAL | ANDA | 21 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-0451 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-0451 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75834-100 | TABLET | 25 mg | ORAL | ANDA | 22 sections |
| Benzphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75834-102 | TABLET | 50 mg | ORAL | ANDA | 22 sections |
| BENZPHETAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76519-1154 | TABLET | 50 mg | ORAL | ANDA | 11 sections |